118 related articles for article (PubMed ID: 37574735)
1. Pre-Analytical Variables Influencing Stability of Blood-Based Biomarkers of Neuropathology.
Panikkar D; Vivek S; Crimmins E; Faul J; Langa KM; Thyagarajan B
J Alzheimers Dis; 2023; 95(2):735-748. PubMed ID: 37574735
[TBL] [Abstract][Full Text] [Related]
2. Impact of pre-analytical sample handling factors on plasma biomarkers of Alzheimer's disease.
Kurz C; Stöckl L; Schrurs I; Suridjan I; Gürsel SÜ; Bittner T; Jethwa A; Perneczky R
J Neurochem; 2023 Apr; 165(1):95-105. PubMed ID: 36625424
[TBL] [Abstract][Full Text] [Related]
3. Effect of Long-Term Storage on the Reliability of Blood Biomarkers for Alzheimer's Disease and Neurodegeneration.
Schubert CR; Paulsen AJ; Pinto AA; Merten N; Cruickshanks KJ
J Alzheimers Dis; 2022; 85(3):1021-1029. PubMed ID: 34924380
[TBL] [Abstract][Full Text] [Related]
4. Plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross-sectional and longitudinal study in the AIBL cohort.
Chatterjee P; Pedrini S; Doecke JD; Thota R; Villemagne VL; Doré V; Singh AK; Wang P; Rainey-Smith S; Fowler C; Taddei K; Sohrabi HR; Molloy MP; Ames D; Maruff P; Rowe CC; Masters CL; Martins RN;
Alzheimers Dement; 2023 Apr; 19(4):1117-1134. PubMed ID: 36574591
[TBL] [Abstract][Full Text] [Related]
5. Stability of blood-based biomarkers of Alzheimer's disease over multiple freeze-thaw cycles.
Keshavan A; Heslegrave A; Zetterberg H; Schott JM
Alzheimers Dement (Amst); 2018; 10():448-451. PubMed ID: 30211292
[TBL] [Abstract][Full Text] [Related]
6. Preanalytical stability of plasma biomarkers for Alzheimer's disease pathology.
Sunde AL; Alsnes IV; Aarsland D; Ashton NJ; Tovar-Rios DA; De Santis G; Blennow K; Zetterberg H; Kjosavik SR
Alzheimers Dement (Amst); 2023; 15(2):e12439. PubMed ID: 37192842
[TBL] [Abstract][Full Text] [Related]
7. Biological variation estimates of Alzheimer's disease plasma biomarkers in healthy individuals.
Brum WS; Ashton NJ; Simrén J; di Molfetta G; Karikari TK; Benedet AL; Zimmer ER; Lantero-Rodriguez J; Montoliu-Gaya L; Jeromin A; Aarsand AK; Bartlett WA; Calle PF; Coşkun A; Díaz-Garzón J; Jonker N; Zetterberg H; Sandberg S; Carobene A; Blennow K
Alzheimers Dement; 2024 Feb; 20(2):1284-1297. PubMed ID: 37985230
[TBL] [Abstract][Full Text] [Related]
8. Plasma biomarkers and genetics in the diagnosis and prediction of Alzheimer's disease.
Stevenson-Hoare J; Heslegrave A; Leonenko G; Fathalla D; Bellou E; Luckcuck L; Marshall R; Sims R; Morgan BP; Hardy J; de Strooper B; Williams J; Zetterberg H; Escott-Price V
Brain; 2023 Feb; 146(2):690-699. PubMed ID: 35383826
[TBL] [Abstract][Full Text] [Related]
9. Effects of certain pre-analytical factors on the performance of plasma phospho-tau217.
Bali D; Hansson O; Janelidze S
Alzheimers Res Ther; 2024 Feb; 16(1):31. PubMed ID: 38331843
[TBL] [Abstract][Full Text] [Related]
10. Plasma tau, neurofilament light chain and amyloid-β levels and risk of dementia; a population-based cohort study.
de Wolf F; Ghanbari M; Licher S; McRae-McKee K; Gras L; Weverling GJ; Wermeling P; Sedaghat S; Ikram MK; Waziry R; Koudstaal W; Klap J; Kostense S; Hofman A; Anderson R; Goudsmit J; Ikram MA
Brain; 2020 Apr; 143(4):1220-1232. PubMed ID: 32206776
[TBL] [Abstract][Full Text] [Related]
11. Cerebrospinal Fluid Aβ42/Aβ40 as a Means to Limiting Tube- and Storage-Dependent Pre-Analytical Variability in Clinical Setting.
Gervaise-Henry C; Watfa G; Albuisson E; Kolodziej A; Dousset B; Olivier JL; Jonveaux TR; Malaplate-Armand C
J Alzheimers Dis; 2017; 57(2):437-445. PubMed ID: 28269771
[TBL] [Abstract][Full Text] [Related]
12. Pre-analytical stability of serum biomarkers for neurological disease: neurofilament-light, glial fibrillary acidic protein and contactin-1.
van Lierop ZYGJ; Verberk IMW; van Uffelen KWJ; Koel-Simmelink MJA; In 't Veld L; Killestein J; Teunissen CE
Clin Chem Lab Med; 2022 May; 60(6):842-850. PubMed ID: 35333481
[TBL] [Abstract][Full Text] [Related]
13. The accuracy and robustness of plasma biomarker models for amyloid PET positivity.
Benedet AL; Brum WS; Hansson O; ; Karikari TK; Zimmer ER; Zetterberg H; Blennow K; Ashton NJ
Alzheimers Res Ther; 2022 Feb; 14(1):26. PubMed ID: 35130933
[TBL] [Abstract][Full Text] [Related]
14. Predicting amyloid PET and tau PET stages with plasma biomarkers.
Jack CR; Wiste HJ; Algeciras-Schimnich A; Figdore DJ; Schwarz CG; Lowe VJ; Ramanan VK; Vemuri P; Mielke MM; Knopman DS; Graff-Radford J; Boeve BF; Kantarci K; Cogswell PM; Senjem ML; Gunter JL; Therneau TM; Petersen RC
Brain; 2023 May; 146(5):2029-2044. PubMed ID: 36789483
[TBL] [Abstract][Full Text] [Related]
15. Association of Plasma Amyloid, P-Tau, GFAP, and NfL With CSF, Clinical, and Cognitive Features in Patients With Dementia With Lewy Bodies.
Bolsewig K; van Unnik AAJM; Blujdea ER; Gonzalez MC; Ashton NJ; Aarsland D; Zetterberg H; Padovani A; Bonanni L; Mollenhauer B; Schade S; Vandenberghe R; Poesen K; Kramberger MG; Paquet C; Bousiges O; Cretin B; Willemse EAJ; Teunissen CE; Lemstra AW;
Neurology; 2024 Jun; 102(12):e209418. PubMed ID: 38830138
[TBL] [Abstract][Full Text] [Related]
16. Blood biomarkers in mild cognitive impairment patients: Relationship between analytes and progression to Alzheimer disease dementia.
Silva-Spínola A; Lima M; Leitão MJ; Bernardes C; Durães J; Duro D; Tábuas-Pereira M; Santana I; Baldeiras I
Eur J Neurol; 2023 Jun; 30(6):1565-1573. PubMed ID: 36880887
[TBL] [Abstract][Full Text] [Related]
17. Effect of Race on Prediction of Brain Amyloidosis by Plasma Aβ42/Aβ40, Phosphorylated Tau, and Neurofilament Light.
Schindler SE; Karikari TK; Ashton NJ; Henson RL; Yarasheski KE; West T; Meyer MR; Kirmess KM; Li Y; Saef B; Moulder KL; Bradford D; Fagan AM; Gordon BA; Benzinger TLS; Balls-Berry J; Bateman RJ; Xiong C; Zetterberg H; Blennow K; Morris JC
Neurology; 2022 Jul; 99(3):e245-e257. PubMed ID: 35450967
[TBL] [Abstract][Full Text] [Related]
18. Dynamics of plasma biomarkers in Down syndrome: the relative levels of Aβ42 decrease with age, whereas NT1 tau and NfL increase.
Mengel D; Liu W; Glynn RJ; Selkoe DJ; Strydom A; Lai F; Rosas HD; Torres A; Patsiogiannis V; Skotko B; Walsh DM
Alzheimers Res Ther; 2020 Mar; 12(1):27. PubMed ID: 32192521
[TBL] [Abstract][Full Text] [Related]
19. The dynamics of plasma biomarkers across the Alzheimer's continuum.
Guo Y; Shen XN; Wang HF; Chen SD; Zhang YR; Chen SF; Cui M; Cheng W; Dong Q; Ma T; Yu JT
Alzheimers Res Ther; 2023 Feb; 15(1):31. PubMed ID: 36750875
[TBL] [Abstract][Full Text] [Related]
20. Cerebrospinal Fluid Biomarkers in Autopsy-Confirmed Alzheimer Disease and Frontotemporal Lobar Degeneration.
Mattsson-Carlgren N; Grinberg LT; Boxer A; Ossenkoppele R; Jonsson M; Seeley W; Ehrenberg A; Spina S; Janelidze S; Rojas-Martinex J; Rosen H; La Joie R; Lesman-Segev O; Iaccarino L; Kollmorgen G; Ljubenkov P; Eichenlaub U; Gorno-Tempini ML; Miller B; Hansson O; Rabinovici GD
Neurology; 2022 Mar; 98(11):e1137-e1150. PubMed ID: 35173015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
